Loading...
Please wait, while we are loading the content...
Similar Documents
Stopping second-generation TKIs in CML
| Content Provider | Scilit |
|---|---|
| Author | Laneuville, Pierre |
| Copyright Year | 2017 |
| Description | In this issue of Blood , [Rea et al][1][1][2] show that rigorously defined suboptimal response or resistance by European LeukemiaNet (ELN) criteria[2][3] to first-line treatment with dasatinib or nilotinib (second-generation tyrosine kinase inhibitor [2G-TKIs]), or later in imatinib-intolerant |
| Related Links | https://ashpublications.org/blood/article-pdf/129/7/805/1402345/blood757302.pdf |
| Ending Page | 806 |
| Page Count | 2 |
| Starting Page | 805 |
| DOI | 10.1182/blood-2016-12-757302 |
| Journal | Blood |
| Issue Number | 7 |
| Volume Number | 129 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2017-02-16 |
| Access Restriction | Open |
| Subject Keyword | Hematology Urology and Nephrology Treatment Kinase Cml Second Generation Tkis Eln Later Intolerant Leukemianet Journal: Blood (Vol- 100, Issue- 7) |
| Content Type | Text |
| Resource Type | Article |